Sysmex (OTCMKTS:SSMXY – Get Free Report) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.415-0.415 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $3.5 billion, compared to the consensus revenue estimate of $3.1 billion.
Sysmex Stock Performance
SSMXY stock opened at $13.36 on Wednesday. The firm has a market cap of $8.12 billion, a PE ratio of 31.80 and a beta of 1.19. The company has a quick ratio of 2.53, a current ratio of 3.40 and a debt-to-equity ratio of 0.23. The business has a 50 day moving average of $12.03 and a 200-day moving average of $10.05. Sysmex has a 12-month low of $8.01 and a 12-month high of $13.75.
Sysmex (OTCMKTS:SSMXY – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.01). Sysmex had a return on equity of 8.01% and a net margin of 7.62%. The business had revenue of $895.73 million for the quarter, compared to the consensus estimate of $859.71 million. Sysmex has set its FY 2026 guidance at 0.415-0.415 EPS. As a group, sell-side analysts expect that Sysmex will post 0.41 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised Sysmex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. Two research analysts have rated the stock with a Hold rating. According to data from MarketBeat, the company has a consensus rating of “Hold”.
Read Our Latest Analysis on Sysmex
About Sysmex
Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and sells diagnostic testing instruments, reagents and related services. Its products are used by hospitals, clinical laboratories and other healthcare providers to analyze patient samples and support medical diagnosis. The company is best known for its hematology testing systems and also offers products for hemostasis, urinalysis, clinical chemistry and immunochemistry, as well as laboratory information systems and support services.
See Also
- Five stocks we like better than Sysmex
- Poll Reveals: Which States Are Most Prepared for a Crisis? [2026]
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.
